Dr. Yogi Chopra, MD
Claim this profileHospital for Sick Children
Studies Beta Thalassemia
Studies Thalassemia
4 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Yogi Chopra, MD is currently running
Reduced Toxicity Conditioning
for Thalassemia
The purpose of this study is to evaluate a novel transplant strategy for the long-term benefit of patients with transfusion dependent high-risk thalassemia.
Recruiting3 awards Phase 1 & 2
Stem Cell Transplant Conditioning
for SCID
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
Recruiting1 award Phase 244 criteria
More about Yogi Chopra, MD
Clinical Trial Related6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Yogi Chopra, MD has experience with
- Abatacept
- Sirolimus
- Lactobacillus Plantarum
- Daily Screening For Delirium
- Busulfan
- Cell Processing For TCRαβ+/CD19+ Depletion
Breakdown of trials Yogi Chopra, MD has run
Beta Thalassemia
Acute Graft-versus-Host Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yogi Chopra, MD specialize in?
Yogi Chopra, MD focuses on Beta Thalassemia and Thalassemia. In particular, much of their work with Beta Thalassemia has involved treating patients, or patients who are undergoing treatment.
Is Yogi Chopra, MD currently recruiting for clinical trials?
Yes, Yogi Chopra, MD is currently recruiting for 2 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Yogi Chopra, MD has studied deeply?
Yes, Yogi Chopra, MD has studied treatments such as Abatacept, Sirolimus, Lactobacillus Plantarum.
What is the best way to schedule an appointment with Yogi Chopra, MD?
Apply for one of the trials that Yogi Chopra, MD is conducting.
What is the office address of Yogi Chopra, MD?
The office of Yogi Chopra, MD is located at: Hospital for Sick Children, Toronto, Ontario M5G 1X8 Canada. This is the address for their practice at the Hospital for Sick Children.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.